Landogrozumab

Landogrozumab
GDF-8
Clinical data
Other names	LY2495655
ATC code	none;
Identifiers
CAS Number	1391726-30-9;
ChemSpider	none;
UNII	B1792M902R;
KEGG	D11235;
Chemical and physical data
Formula	C6338H9790N1694O1988S42
Molar mass	142874.43 g·mol−1

Landogrozumab (

INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.^[1]^[2]

The drug was developed by Eli Lilly and Company.

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.
^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.

[2] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).

[1]

[2]